BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6578873)

  • 21. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
    Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
    Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer.
    Martoni A; Pacciarini MA; Pannuti F
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):803-6. PubMed ID: 3862582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase II study of 4-demethoxydaunorubicin in metastatic breast neoplasms].
    Lionetto R; Ardizzoni A; Repetto L; Pronzato P; Sertoli MR; Rosso R
    G Ital Chemioter; 1985; 32(1):59-60. PubMed ID: 3868637
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
    Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias.
    Carella AM; Santini G; Martinengo M; Marmont AM
    Haematologica; 1984; 69(6):767-8. PubMed ID: 6441755
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
    Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
    Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of idarubicin in advanced cervical carcinoma.
    Hakes TB; Dougherty JB; Raymond V
    Am J Clin Oncol; 1986 Jun; 9(3):262-3. PubMed ID: 3460321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.
    Milroy R; Cummings J; Kaye SB; Banham SW
    Cancer Chemother Pharmacol; 1987; 20(1):75-7. PubMed ID: 3040287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
    Kavanagh JJ; Copeland LJ; Gershenson DM; Saul PB; Edwards CL
    Gynecol Oncol; 1986 May; 24(1):23-6. PubMed ID: 3457752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited activity of carboplatin in malignant lymphoma.
    Danieu L; Warrell RP
    Cancer Treat Rep; 1986 Jul; 70(7):931-2. PubMed ID: 3521851
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
    Sessa C; Tschopp L; Fopp M; Cavalli F
    Invest New Drugs; 1985; 3(4):357-9. PubMed ID: 3866755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of 4-demethoxydaunorubicin.
    Bonfante V; Ferrari L; Villani F; Bonadonna G
    Invest New Drugs; 1983; 1(2):161-8. PubMed ID: 6590530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of 4-demethoxydaunorubicin with single i.v. doses.
    Kaplan S; Martini A; Varini M; Togni P; Cavalli F
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1303-6. PubMed ID: 6962779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Polychemotherapy of malignant lymphomas].
    Vermel' AE; RaevskiÄ­ IG
    Sov Med; 1976 Aug; (8):42-7. PubMed ID: 1006422
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
    Corsini C; Ghielmini M; Mancuso P; Tealdo F; Paolucci M; Zucchetti M; Ferrucci PF; Cocorocchio E; Mezzetti M; Mori A; Riggi M; D'Incalci M; Martinelli G
    Br J Cancer; 2000 Feb; 82(3):524-8. PubMed ID: 10682659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology and phase I clinical studies of daunorubicin in patients with advanced malignancies.
    Woodcock TM; Allegra JC; Richman SP; Lalley K; Kubota TT; Blumenreich MS; Gentile P; Jones M; Seeger J
    Semin Oncol; 1984 Dec; 11(4 Suppl 3):28-32. PubMed ID: 6505715
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin.
    Cancer Clin Trials; 1980; 3(2):115-20. PubMed ID: 7428135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.